20cm速递｜创业板医药ETF国泰（159377）盘中飘红，高血压创新疗法突破或成行业催化因素

Group 1 - The core viewpoint is that hypertension is a significant health issue in China, with an estimated 245 million patients, making hypertension control crucial for reducing cardiovascular risks [1] - Renal denervation (RDN) is highlighted as a minimally invasive intervention that effectively controls blood pressure, with its efficacy validated through multiple clinical trials [1] - The approval of Medtronic's Simplicity Spyral and ReCor Paradise by the FDA marks a significant milestone for RDN therapy, indicating growing acceptance and potential for market expansion [1] Group 2 - Four RDN products have been approved in China, with domestic manufacturers innovating in electrode design and access methods to create differentiated advantages [1] - As evidence from evidence-based medicine accumulates, RDN is expected to become a first-line treatment for drug-resistant hypertension, with more multi-energy products being approved domestically and internationally [1] - The Guotai ETF (159377) tracks the Chuangyi Pharmaceutical Index (399275), which includes stocks from the pharmaceutical, medical device, and healthcare services sectors, reflecting the overall performance of innovative growth companies in the biotech industry [1]